September 25, 2019
Financing Will Support Launch of Access Vascular's HydroPICC
September 26, 2019—Access Vascular announced $6 million in new funding from new and existing investors to support the launch of its next-generation FDA-cleared HydroPICC peripherally inserted central catheter, as well as the initiation of the company's first postmarket registry study.
Access Vascular develops intravenous devices, including novel biomaterials designed to minimize the risk of bloodstream infection, catheter thrombosis, and vein trauma.
The new funding will also support product development as the company seeks to expand its portfolio of reduced thrombosis intravenous devices. The company anticipates making an FDA submission for a second product next year.
According to Access Vascular, its biomaterial platform has demonstrated the ability to minimize thrombus accumulation. Future innovations in the company's pipeline could actively combat bloodstream infections for the life of the catheter or allow insertion of a catheter through difficult or stenosed vessels.